PMID- 36004273
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220826
IS  - 2666-2736 (Electronic)
IS  - 2666-2736 (Linking)
VI  - 10
DP  - 2022 Jun
TI  - Primary pulmonary synovial sarcoma.
PG  - 404-414
LID - 10.1016/j.xjon.2022.02.014 [doi]
AB  - OBJECTIVE: Primary pulmonary synovial sarcoma (PPSS) is extremely rare. This 
      study aims to identify the clinicopathologic and therapeutic factors determining 
      survival in PPSS. METHODS: We performed a retrospective analysis of 121 patients 
      from the Surveillance, Epidemiology, and End Results Database as well as 12 
      patients from our own institution diagnosed with PPSS. Patient survival was 
      evaluated using the Kaplan-Meier method. RESULTS: The median survival time for 12 
      PPSS patients in our institution was 78 months. Postoperative chemotherapy 
      (P = .027 for overall survival and P = .035 for disease-specific survival) was 
      associated with superior survival, whereas pneumonectomy (P = .011 for overall 
      survival and P = .006 for disease-specific survival) was associated with worse 
      survival. Single lobe involvement (P = .022) and the absence of lymph node 
      involvement (P = .045) were associated with improved disease-specific survival 
      and overall survival, respectively. In the Surveillance, Epidemiology, and End 
      Results Database, the median survival time was 23 months. Significantly superior 
      survival was observed in patients with earlier American Joint Committee on Cancer 
      stage (Ⅰ-Ⅱ) (P < .001 for both overall survival and disease-specific survival). 
      Patients who were diagnosed within the recent decade did not achieve a better 
      survival (P = .599 for overall survival and P = .596 for disease-specific 
      survival). CONCLUSIONS: PPSS was aggressive with a very poor prognosis. The 
      seventh American Joint Committee on Cancer stage might aid in predicting 
      survival. Pneumonectomy and lymph node involvement might be associated with worse 
      survival, whereas single lobe involvement and postoperative chemotherapy might be 
      associated with improved survival.
CI  - (c) 2022 The Author(s).
FAU - Wang, Weixi
AU  - Wang W
AD  - Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Guo, Junhong
AU  - Guo J
AD  - Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Bao, Minwei
AU  - Bao M
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Liu, Xiaogang
AU  - Liu X
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Ye, Cong
AU  - Ye C
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220224
PL  - Netherlands
TA  - JTCVS Open
JT  - JTCVS open
JID - 101768541
PMC - PMC9390693
OTO - NOTNLM
OT  - AJCC, American Joint Committee on Cancer
OT  - DSS, disease-specific survival
OT  - LN, lymph node
OT  - OS, overall survival
OT  - PPSS, primary pulmonary synovial sarcoma
OT  - SEER database
OT  - SEER, Surveillance, Epidemiology, and End Results
OT  - SS, synovial sarcoma
OT  - STS, soft tissue sarcoma
OT  - outcomes
OT  - primary pulmonary synovial sarcoma
OT  - single center study
EDAT- 2022/08/26 06:00
MHDA- 2022/08/26 06:01
PMCR- 2022/02/24
CRDT- 2022/08/25 02:32
PHST- 2021/01/26 00:00 [received]
PHST- 2022/02/16 00:00 [accepted]
PHST- 2022/08/25 02:32 [entrez]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/26 06:01 [medline]
PHST- 2022/02/24 00:00 [pmc-release]
AID - S2666-2736(22)00068-7 [pii]
AID - 10.1016/j.xjon.2022.02.014 [doi]
PST - epublish
SO  - JTCVS Open. 2022 Feb 24;10:404-414. doi: 10.1016/j.xjon.2022.02.014. eCollection 
      2022 Jun.